Aurinia Pharmaceuticals (AUPH) Misses Q1 EPS by 1c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q1 EPS of ($0.27), $0.01 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $21.58 million.

The company maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS for 2022.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• Beyond Air, Inc. (XAIR) Tops Q1 reported Q1 Revenue ; Offers Guidance
• Aeroflex Holdings (ARX) Tops Q2 EPS by 15c